The Pharma Letter features an interview with Dewpoint’s Chief Scientific Officer Isaac Klein and SVP, Head of Research Ann Boija where […]

The Pharma Letter features an article about Dewpoint Therapeutics, highlighting the excitement and confidence at the company in the selection of […]

The Pharma Letter features an article about Dewpoint Therapeutics, highlighting the Fast Track designation for DPTX3186, the company’s first in class […]

The Clinical Trial Vanguard features an article about Dewpoint Therapeutics, highlighting the closing of our series D financing and our […]

The Pharma Letter features an article about Dewpoint Therapeutics, highlighting our exciting milestones in 2024 and our plans to forge new […]

The Pharma Letter features a major milestone for Dewpoint Therapeutics – the nomination of our first development candidate, DPTX3186, as a […]

The Pharma Letter features a Dewpoint Therapeutics company profile, discussing our revolutionary condensate science with broad applicability across therapeutic areas, AI-powered […]

The Pharma Letter features an interview with our CEO Ameet Nathwani: “Dewpoint Therapeutics was founded on the ground-breaking realization that […]

Dewpoint congratulates our scientific founder, Tony Hyman, for his election to the German Academy of Sciences Leopoldina. This prestigious award […]

A Nature review of condensate focused start-ups has described Dewpoint as the “field’s frontrunner’. The article has profiled three condensate […]